gatifloxacin has been researched along with Tuberculosis, Drug-Resistant in 15 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Moxifloxacin was effective against mutant strain GyrB D500N, with the lowest MIC (0." | 5.36 | Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. ( Aubry, A; Chauffour, A; Farinotti, R; Fernandez, C; Jarlier, V; Lott, MC; Poissy, J; Veziris, N, 2010) |
| "Ineffectively treated tuberculosis (TB) is associated with substantial morbidity and mortality." | 2.53 | Human Tuberculosis. III. Current and Prospective Approaches in Anti-Tubercular Therapy. ( Corelli, F; Frosini, M; Saponara, S; Sgaragli, G, 2016) |
| "Gatifloxacin has a susceptible dose-dependent zone at MICs 0." | 1.48 | Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis. ( Ambrose, PG; Bendet, P; Bhavnani, SM; Deshpande, D; Gumbo, T; Gumusboga, M; Koeuth, T; McIlleron, H; Pasipanodya, JG; Smythe, W; Srivastava, S; Thwaites, G; Van Deun, A, 2018) |
| "To assess outcome and adverse drug events with a standardised 12-month regimen for MDR-TB among second-line drug naïve patients." | 1.42 | High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. ( Abena Foe, JL; Aït-Khaled, N; Kuaban, C; Noeske, J; Rieder, HL; Trébucq, A, 2015) |
| "The number of pulmonary tuberculosis (PTB) patients reported with resistance to first-line anti-tuberculosis drugs after a standardized retreatment regimen in Cameroon is increasing." | 1.38 | Early results of systematic drug susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon. ( Abena Foe, JL; Fon, E; Noeske, J; Voelz, N, 2012) |
| "Moxifloxacin was effective against mutant strain GyrB D500N, with the lowest MIC (0." | 1.36 | Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. ( Aubry, A; Chauffour, A; Farinotti, R; Fernandez, C; Jarlier, V; Lott, MC; Poissy, J; Veziris, N, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, YQ | 1 |
| Zhang, S | 1 |
| Zhao, F | 1 |
| Gao, C | 1 |
| Feng, LS | 1 |
| Lv, ZS | 1 |
| Xu, Z | 1 |
| Wu, X | 1 |
| Nie, Q | 1 |
| Tao, L | 1 |
| Li, Y | 1 |
| Chen, N | 1 |
| Chen, H | 2 |
| Zhou, Y | 1 |
| Wang, Y | 1 |
| Tang, Q | 1 |
| Wang, X | 1 |
| Huang, C | 1 |
| Yang, C | 1 |
| Van Deun, A | 7 |
| Decroo, T | 2 |
| Kuaban, C | 2 |
| Noeske, J | 3 |
| Piubello, A | 3 |
| Aung, KJM | 1 |
| Rieder, HL | 5 |
| Ngabonziza, JCS | 1 |
| Migambi, P | 1 |
| Niyigena, EB | 1 |
| Dusabe, T | 1 |
| Habimana, YM | 1 |
| Ushizimpumu, B | 1 |
| Mulders, W | 1 |
| Affolabi, D | 1 |
| Supply, P | 1 |
| de Jong, BC | 1 |
| Rigouts, L | 1 |
| Chiang, CY | 2 |
| Trébucq, A | 2 |
| Deshpande, D | 1 |
| Pasipanodya, JG | 1 |
| Srivastava, S | 1 |
| Bendet, P | 1 |
| Koeuth, T | 1 |
| Bhavnani, SM | 1 |
| Ambrose, PG | 1 |
| Smythe, W | 1 |
| McIlleron, H | 1 |
| Thwaites, G | 1 |
| Gumusboga, M | 1 |
| Gumbo, T | 1 |
| Lalloo, UG | 1 |
| Aung, KJ | 1 |
| Declercq, E | 1 |
| Sarker, MR | 1 |
| Das, PK | 1 |
| Hossain, MA | 1 |
| Harouna, SH | 1 |
| Souleymane, MB | 1 |
| Boukary, I | 1 |
| Morou, S | 1 |
| Daouda, M | 1 |
| Hanki, Y | 1 |
| Aït-Khaled, N | 1 |
| Abena Foe, JL | 2 |
| Sgaragli, G | 1 |
| Frosini, M | 1 |
| Saponara, S | 1 |
| Corelli, F | 1 |
| Poissy, J | 1 |
| Aubry, A | 1 |
| Fernandez, C | 1 |
| Lott, MC | 1 |
| Chauffour, A | 1 |
| Jarlier, V | 1 |
| Farinotti, R | 1 |
| Veziris, N | 1 |
| Voelz, N | 1 |
| Fon, E | 1 |
| Yadav, V | 1 |
| Deopujari, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB[NCT05278988] | Phase 4 | 60 participants (Anticipated) | Interventional | 2021-04-01 | Recruiting | ||
| Culture Free Diagnosis and Follow-up of Multidrug Resistant Tuberculosis Patients[NCT03303963] | 3,356 participants (Actual) | Observational | 2017-05-04 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for gatifloxacin and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
Isoniazid derivatives and their anti-tubercular activity.
Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Isoniazid; Mycobacterium tuberculosis; Tuber | 2017 |
Human Tuberculosis. III. Current and Prospective Approaches in Anti-Tubercular Therapy.
Topics: Antitubercular Agents; Bacterial Proteins; Clinical Trials as Topic; Fluoroquinolones; Gatifloxacin; | 2016 |
13 other studies available for gatifloxacin and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
High-dose gatifloxacin-based shorter treatment regimens for MDR/RR-TB.
Topics: Antitubercular Agents; Gatifloxacin; Humans; Isoniazid; Pyrazinamide; Treatment Outcome; Tuberculosi | 2022 |
Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Bangladesh; Cameroon; Child; Drug | 2019 |
Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis.
Topics: Antitubercular Agents; Clofazimine; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; | 2020 |
Should gatifloxacin be included in the model list of essential medicines?
Topics: Drugs, Essential; Gatifloxacin; Humans; Tuberculosis, Multidrug-Resistant; World Health Organization | 2018 |
Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
Topics: Antitubercular Agents; Gatifloxacin; Humans; Lung; Microbial Sensitivity Tests; Monte Carlo Method; | 2018 |
Short-course Bangladesh regimen for multidrug-resistant tuberculosis: a step in the right direction?
Topics: Anti-Bacterial Agents; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Tuberculosis, Multidrug | 2014 |
Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bangladesh; Child; Clofazimine; Dose-Response Relati | 2014 |
Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bangladesh; Child; Clofazimine; Dose-Response Relati | 2014 |
Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bangladesh; Child; Clofazimine; Dose-Response Relati | 2014 |
Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bangladesh; Child; Clofazimine; Dose-Response Relati | 2014 |
High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses.
Topics: Adolescent; Adult; Aged; Body Mass Index; Body Weight; Clofazimine; Dose-Response Relationship, Drug | 2014 |
High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Cameroon; Clofazimine; Cohort Studies; Confidence In | 2015 |
Gatifloxacin for short, effective treatment of multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Bangladesh; Blood Glucose; Cameroon; Dose-Response Relationship, Drug; Fluoro | 2016 |
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
Topics: Animals; Antitubercular Agents; Aza Compounds; DNA Gyrase; Enoxacin; Fluoroquinolones; Gatifloxacin; | 2010 |
Early results of systematic drug susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon.
Topics: Adult; Antitubercular Agents; Cameroon; Drug Resistance, Multiple, Bacterial; Feasibility Studies; F | 2012 |
Gatifloxacin and dysglycemia in older adults.
Topics: Anti-Bacterial Agents; Fluoroquinolones; Gatifloxacin; Humans; Hyperglycemia; Hypoglycemia; Mortalit | 2006 |